Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer

被引:15
|
作者
Minami, Seigo [1 ,2 ]
Ihara, Shouichi [1 ]
Komuta, Kiyoshi [2 ]
机构
[1] Osaka Police Hosp, Dept Resp Med, Tenn Ku, 10-31 Kitayama Cho, Osaka, Osaka 5430035, Japan
[2] Daini Osaka Police Hosp, Dept Resp Med, Tenn Ku, 2-6-40 Karasugatsuji, Osaka 5438922, Japan
关键词
Gustave Roussy immune score; Royal Marsden Hospital prognostic score; Extensive disease; Small cell lung cancer; Neutrophil-to-lymphocyte ratio; Number of metastatic sites; Lactate dehydrogenase; Serum albumin; TO-LYMPHOCYTE RATIO; PHASE-I; PROSPECTIVE VALIDATION; LACTATE-DEHYDROGENASE;
D O I
10.14740/wjon1275
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The Royal Marsden Hospital prognostic score (RMH score) and the Gustave Roussy inunune score (GRIm-score) were developed in order to select more suitable patient for phase I trials. Lactate dehydrogenase (LDH) and serum albumin concentration are common risk factors to these two systems. As the third risk factor, the RMII score and the GRIm-score adopt number of metastatic sites and neutrophil-to-lymphocyte ratio (NLR), respectively. We aimed to investigate whether these two systems are also useful for extensive disease of small cell lung cancer (ED-SCLC). Methods: We retrospectively collected 128 patients who had initiated platinum-based chemotherapy at our hospital between September 2007 and March 2018. We divided our patients into low (score 0 - 1) and high (2 - 3) score groups, and compared overall survival (OS) and progression-free survival (PFS) between them. Multivariate Cox proportional hazard analyses found prognostic factors of survival times. Results: Regarding GRIm-score, OS was significantly shorter in high score group than in low score group (median 6.1 vs. 11.4 months, P < 0.01), while no significant difference was observed in PFS (median 4.7 vs. 5.0 months, P = 0.12). Both OS (median 6.9 vs. 12.4 months, P < 0.01) and PFS (median 4.4 vs. 5.4 months, P = 0.01) were significantly shorter in high RMH score group than in low group. Multivariate analyses detected both high GRIm-score (hazard ratio (HR) 1.80, 95% confidence interval (CI) 1.20 - 2.72, P < 0.01) and high RMH score (HR 1.93, 95% CI 1.27 - 2.92, P < 0.01) as independent worse prognostic factors of OS, and then only high RMI1 score (FIR 1.53, 95% CI 1.04 - 2.25, P = 0.03) as independent worse prognostic factor of PFS. Conclusions: Both RMH score and GRIm-score are useful as inde- pendent prognostic factors of OS in ED-SCLC. However, only RMH score is an independent prognostic factor of PFS.
引用
收藏
页码:98 / 105
页数:8
相关论文
共 50 条
  • [41] Gustave Roussy Immune Score based on a three-category risk assessment scale serves as a novel and effective prognostic indicator for surgically resectable early-stage non-small-cell lung cancer: A propensity score matching retrospective cohort study
    Li, Shuang-Jiang
    Zhao, Liang
    Wang, Hong-Yu
    Zhou, Hai-Ning
    Ju, Juan
    Du, Heng
    Che, Guo-Wei
    INTERNATIONAL JOURNAL OF SURGERY, 2020, 84 : 25 - 40
  • [42] Lung Immune Prognostic Index (LIPI): Prognostic predictor for patients with extensive-stage small-cell lung cancer
    Majidova, Nargiz
    Seyyar, Mustafa
    Guren, Ali Kaan
    Kocaaslan, Erkam
    Kircali, Muhammed Fatih
    Sever, Nadiye
    Erel, Pinar
    Agyol, Yesim
    Pacaci, Burak
    Tunc, Mustafa Alperen
    Bayoglu, Ibrahim Vedat
    MARMARA MEDICAL JOURNAL, 2025, 38 (01): : 24 - 28
  • [43] Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study
    Tanabe, Kenji
    Kobayashi, Shuichiro
    Maezawa, Yuya
    Ishihara, Kensaku
    Inoue, Naoki
    Izumi, Keita
    Fujiwara, Motohiro
    Toide, Masahiro
    Yamamoto, Takanobu
    Uehara, Sho
    Araki, Saori
    Inoue, Masaharu
    Takazawa, Ryoji
    Numao, Noboru
    Ohtsuka, Yukihiro
    Tanaka, Hajime
    Yoshida, Soichiro
    Fujii, Yasuhisa
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (09) : 1302 - 1310
  • [44] The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer
    Endo, Satoshi
    Imai, Hisao
    Shiono, Ayako
    Hashimoto, Kosuke
    Miura, Yu
    Okazaki, Shohei
    Abe, Takanori
    Mouri, Atsuto
    Kaira, Kyoichi
    Masubuchi, Ken
    Masubuchi, Takeshi
    Kobayashi, Kunihiko
    Minato, Koichi
    Kato, Shingo
    Kagamu, Hiroshi
    ONCOLOGY, 2024,
  • [45] Analysis of the Prognostic Factors of Extensive Disease Small-Cell Lung Cancer Patients in Tokushima University Hospital
    Ogino, Hirokazu
    Hanibuchi, Masaki
    Kakiuchi, Soji
    Saijo, Atsuro
    Tezuka, Toshifumi
    Toyoda, Yuko
    Tobiume, Makoto
    Otsuka, Kenji
    Sakaguchi, Satoshi
    Goto, Hisatsugu
    Arisawa, Kokichi
    Nishioka, Yasuhiko
    JOURNAL OF MEDICAL INVESTIGATION, 2016, 63 (3-4): : 286 - 293
  • [46] Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer
    Jiang, Hao
    Li, Borui
    Wu, Min
    Wang, Qimei
    Li, Yijin
    BMC CANCER, 2024, 24 (01)
  • [47] A commentary on "Gustave Roussy immune score based on a three-category risk assessment scale serves as a novel and effective prognostic indicator for surgically resectable early-stage non-small-cell lung cancer: A propensity score matching retrospective cohort study"
    Lin, M. M. Xiaoyun
    Liu, Hua
    INTERNATIONAL JOURNAL OF SURGERY, 2021, 89
  • [48] Identification of an Individualized Immune-Related Prognostic Risk Score in Lung Squamous Cell Cancer
    Zhuang, Yuan
    Li, Sihan
    Liu, Chang
    Li, Guang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [49] Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer
    Sonehara, Kei
    Tateishi, Kazunari
    Komatsu, Masamichi
    Yamamoto, Hiroshi
    Hanaoka, Masayuki
    THORACIC CANCER, 2020, 11 (06) : 1578 - 1586
  • [50] ASO Visual Abstract: Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study
    Nakazawa, Nobuhiro
    Sohda, Makoto
    Ubukata, Yasunari
    Kuriyama, Kengo
    Kimura, Akiharu
    Kogure, Norimichi
    Hosaka, Hisashi
    Naganuma, Atsushi
    Sekiguchi, Masanori
    Saito, Kana
    Ogata, Kyoichi
    Sano, Akihiko
    Sakai, Makoto
    Ogawa, Hiroomi
    Shirabe, Ken
    Saeki, Hiroshi
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (12) : 7409 - 7409